Who We Are:

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

What We Do:

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we submitted a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 and XEN1720 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are being developed for pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

About the Role:

We are seeking a Director, Strategic Engagements, Northeast, to join our team. The individual will be an integral member of the Commercial team and will support commercially focused HCP engagement activities for Azetukalner.

Key primary responsibility is to support key US Commercial Strategic market development strategies for the epilepsy launch. Individuals should be an exceptional business leader with deep epilepsy experience who will work Regionally to maintain: 1) KOL Engagement and 2) Uncover key market impact drivers 3) Support regional business planning across matrix colleagues. This role will ensure close working relationships with cross-functional partners in a compliant manner.

This position requires close collaboration with the Commercial team, Medical Affairs and other key business partners to elevate corporate brand awareness/ advocacy. This role requires demonstrated ability to thrive in a dynamic and ambiguous environment. Position will require greater than 50% travel (can be up to 75% travel) to field-based educational events (many occurring on weekends). This includes internal meetings, advisory boards, medical meetings, and congresses.

This position reports to the Senior Director, Customer Engagement, and will be fully remote.

RESPONSIBILITIES

· Identify, cultivate, and maintain long-term relationships with national and regional epilepsy KOLs, advisors, and other influential stakeholders.

· Own commercial KOL influence mapping, including stakeholder profiling, engagement strategies, and communication plans that inform customer prioritization and commercial planning.

· Monitor and synthesize stakeholder insights, treatment trends, unmet needs, and competitive dynamics, translating findings into actionable recommendations that inform commercial strategy, launch readiness, and regional business decisions.

· Serve as a strategic advisor to Commercial leadership by providing market intelligence, stakeholder perspectives, and recommendations that shape launch planning, customer engagement strategies, and business priorities.